Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience.

Jérémy BaudeJulie NiogretPierre JacobFlorian BardetIsabelle DesmoulinsSylvie ZanettaCourèche KaderbhaiLoïck GallandDidier MayeurBenjamin DelattreLuc CormierSylvain Ladoire

Published in: Cancers (2024)

Reports of the clinical results of CE suggest that we should not mix PSC-NE and castration-resistant adenocarcinoma of the prostate. In patients with heavily pretreated adenocarcinoma, the benefit/risk ratio of CE chemotherapy seems unfavorable due to poor response and high toxicity.

Keyphrases

prostate cancer
squamous cell carcinoma
locally advanced
radical prostatectomy
phase ii study
small cell lung cancer
rectal cancer
oxidative stress
energy transfer
emergency department
radiation therapy
clinical trial
benign prostatic hyperplasia
combination therapy
quantum dots